News
The Augurex team brings together leading scientific, clinical, technical and commercial expertise to ensure that our research translates into advanced diagnostics for improved patient outcomes.
2018 Ready to Rocket Winner
Honored to be recognized by "Ready to Rocket" as one of the 10 featured Life Sciences companies to experience accelerated growth. We're excited for the future! About Ready to Rocket: Ready to Rocket is a unique business recognition list that profiles technology...
High 14-3-3η Amplifies the Risk of Rapid Radiographic Progression
In a study of over 800 rheumatoid arthritis (RA) patients, presented this week at the Canadian Rheumatology (CRA) Association Meeting, it was shown that a positive 14-3-3η blood test amplified the risk of rapid joint damage progression when added to current measures....
BC-Led Digital Technology Supercluster Awarded Federal Funding to Transform Canada’s Fastest-Growing Tech Sector
As a founding member, we are thrilled that the BC-led #DigitalSupercluster has been chosen. Truly an exciting day for technology innovation in Canada!
Canada’s Most Powerful Women: Top 100 Current Winners
Augurex CEO Norma Biln was awarded Canada's Most Powerful Women: Top 100 Award for her extraordinary leadership and continued drive to inspire others. The Top 100 Award Winner community now includes 1,005 remarkable women who together celebrate accomplishments, share...
Children get arthritis too; Data on a blood test to help characterize JIA and its subtypes.
At the world’s premier arthritis conference, the American College of Rheumatology Annual Meeting (ACR), taking place in San Diego on November 3rd-8th, leading investigators from the United States, Canada and Egypt will present new data on the 14-3-3η blood test....
USPTO Issues 14-3-3η Patent: Good News for RA Patients
NEWS RELEASE | OCTOBER 17, 2017 Vancouver, BC — Augurex Life Sciences Corp is proud to announce that 14-3-3η, a novel rheumatoid arthritis (RA) biomarker, is paving a future for better patient outcomes. Today the U.S Patent and Trademark Office (USPTO) has issued...
Explaining The “Why”; 14-3-3η’s Biological Role As A Basis For Its Clinical Utility
Vancouver, BC – June 13, 2017. At the annual European congress of rheumatology meeting, The European League Against Rheumatism (EULAR), taking place in Madrid, Spain on June 14-17, investigators present the continued understanding of 14-3-3η's role in rheumatoid...
Serial 14-3-3η testing: informing RA flare and joint damage risk as you treat-to-target
Vancouver, BC – April 18, 2017. At the premier Asia-Pacific rheumatology conference, the Japan College of Rheumatology Annual Scientific Meeting (JCR), taking place in Fukuoka, Japan on April 20-22, international investigators from the United States, Canada, and...
Accelerating the Transformation of Patient Care
Please see the Genome BC news release from last week. Augurex is proud of and appreciates the ongoing support that we receive from provincial and federal government programs to expedite JOINTstat™ access to patients worldwide. Augurex is recognized as an emerging...
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Home
Products
Science
About
News
Careers
Contact